




PHARMACEUTICAL 2019

IMMUNE DESIGN CORP.
Rank 91 of 363





PHARMACEUTICAL 2019

IMMUNE DESIGN CORP. Rank 91 of 363

The relative strengths and weaknesses of IMMUNE DESIGN CORP. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of IMMUNE DESIGN CORP. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 110% points. The greatest weakness of IMMUNE DESIGN CORP. is the variable Research and Development, reducing the Economic Capital Ratio by 36% points.

The company's Economic Capital Ratio, given in the ranking table, is 187%, being 150% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	100,225
Cost of Goods Sold	1,435
Intangible Assets	0
Liabilities, Current	8,845
Liabilities, Non-Current	0
Other Assets	200
Other Compr. Net Income	2,339
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Other Revenues	2,196
Property and Equipment	535
Research and Development	42,415
Selling, General and Administrative Expense	15,396

Output Variable	Value in 1000 USD
Assets	100,960
Liabilities	8,845
Expenses	59,246
Revenues	2,196
Stockholders Equity	92,115
Net Income	-57,050
Comprehensive Net Income	-55,880
Economic Capital Ratio	187%